Business Wire

EUSA Pharma Announces First Patient Enrolled in a Randomised Phase 3 Clinical Trial Investigating Siltuximab in Hospitalised Patients with COVID-19- or Another Respiratory Virus Infection-Associated Acute Respiratory Distress Syndrome (ARDS)

Share

EUSA Pharma (UK) Limited (“EUSA Pharma”), a global biopharmaceutical company, announced today that the first patient has been enrolled in the SILtuximab in Viral ARDS (‘SILVAR’) study at the Sparrow Hospital in Lansing, Michigan. The ‘SILVAR’ study is a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel-arm, Phase 3 study designed to confirm the encouraging results of the observational, single-centre, control-cohort in the Siltuximab In Serious COVID-19 (‘SISCO’) study.1 The results from 30 patients treated with siltuximab in the ‘SISCO’ study compared with 30 matched controls, showed that treatment with siltuximab led to a 54% reduction in risk of 30-day all-cause mortality.2

This pivotal study will evaluate the efficacy and safety of standard of care (SOC) with or without intravenous siltuximab in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection. Unlike previous studies of agents targeting the interleukin-6 (IL-6) signalling pathway, the ‘SILVAR’ study has been rationally designed to only enrol those hospitalised patients suffering from serious viral acute respiratory distress syndrome (ARDS) in a hyperinflammatory state that will most likely benefit from the addition of an anti-IL-6 immunomodulator such as siltuximab.

Lee Morley, Chief Executive Officer, EUSA Pharma, said, “We are delighted to have enrolled the first patient in the ‘SILVAR’ study of siltuximab, a monoclonal antibody that binds to and neutralises IL-6, an important mediator of the immune response to infection. This clinical trial represents an important step in finding a solution for hospitalised patients with serious respiratory complications due to an over reactive immune response to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection that is not fully responsive to corticosteroid therapy, as well as those with any other respiratory virus infection associated with serious ARDS.”

Zainab Shahid, MD, FACP, infectious disease physician with Atrium Health and Lead Principal Investigator on the ‘SILVAR’ study, said, “Patients with serious viral ARDS have some of the highest mortality rates despite recent improvements in intensive care. The ‘SILVAR’ study is a very important step to potentially confirm the encouraging results of the Italian observational cohort-control ‘SISCO’ study in a prospective, randomised, controlled fashion.”

References
1. Siltuximab In Serious COVID-19 (SISCO) study (NCT04322188); https://www.clinicaltrials.gov/ct2/show/NCT04322188
2. Gritti G, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv June 2020; DOI: https://doi.org/10.1101/2020.04.01.20048561.

-----

About the ‘SILVAR’ Study
SIL
tuximab in Viral ARDS (‘SILVAR’) is an FDA-approved, prospective, multicentre, randomised, double-blind, placebo-controlled, parallel-arm, Phase 3 clinical trial designed to compare the efficacy and safety of intravenous siltuximab plus SOC to intravenous normal saline plus SOC in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with ARDS. This US multicentre clinical trial will aim to enrol approximately 555 patients with serious viral ARDS and elevated serum levels of IL-6 as measured by its qualified C-reactive protein (CRP) surrogate. The primary objective is to demonstrate a significant reduction in 28-day mortality with the addition of siltuximab to SOC. Secondary objectives are to compare other measures of efficacy between both treatment arms and to evaluate the safety, tolerability, exposure, and immunogenicity of siltuximab in this patient population and treatment setting. For more information, please visit www.clinicaltrials.gov/ct2/show/NCT04616586.

About Siltuximab
Siltuximab is a monoclonal antibody that directly neutralises IL-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions. It is currently approved by the US Food and Drug Administration (FDA) and the European Commission (EC), as well as health regulatory authorities in several other jurisdictions worldwide, for the treatment of adult patients with Multicentric Castleman Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. EUSA Pharma has exclusive rights to siltuximab (SYLVANT® ▼) globally. Indications and Usage of SYLVANT – See EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information for additional information.

About EUSA Pharma
Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company is headquartered in Hemel Hempstead, England (UK), and has extensive commercial operations in the United States and Europe, alongside a direct presence in selected other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and it is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information, please visit www.eusapharma.com.

About Atrium Health
Atrium Health is a nationally recognized leader in shaping health outcomes through innovative research, education and compassionate patient care. Atrium Health is an integrated, non-profit health system with more than 70,000 teammates serving patients at 42 hospitals and more than 1,500 care locations. It provides care under the Wake Forest Baptist Health name in the Winston-Salem, North Carolina, region and Navicent Health in Georgia. Atrium Health is renowned for its top-ranked pediatric, cancer and heart care, as well as organ transplants, burn treatments and specialized musculoskeletal programs. A recognized leader in experiential medical education and ground breaking research, Wake Forest School of Medicine is the academic core of the enterprise, including Wake Forest Innovations, which is advancing new medical technologies and biomedical discoveries. Atrium Health is also a leading-edge innovator in virtual care and mobile medicine, providing care close to home and in the home. Ranked among U.S. News & World Report’s Best Hospitals for cancer treatment and in eight pediatric specialties, Atrium Health has also received the American Hospital Association’s Quest for Quality Prize and was the recipient of the 2020 Centers for Medicare & Medicaid Services Health Equity Award for its efforts to reduce racial and ethnic disparities in care. With a commitment to every community it serves, Atrium Health seeks to improve health, elevate hope and advance healing – for all, providing more than $2 billion per year in free and uncompensated care and other community benefits.

Contact information

EUSA Media
Rebecca Kerr
+44 7909 703627
media@eusapharma.com

GL-NPS-2000043. December 2020

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

myPOS Releases a High-class Android Payment Terminal at an Unbeatable Price on the European Market28.1.2021 13:47:00 EETPress release

As the demand for more advanced payment devices grows, European fintech provider myPOS (www.mypos.com) introduces yet another payment innovation - the new myPOS Carbon, which combines the intelligent Android OS with shock, dust and water resistance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005525/en/ The new myPOS Carbon combines the intelligence of Android 9.0 with dust, water and shock resistance at an unbeatable price. (Photo: Business Wire) Traditional POS terminals with keys are gradually being replaced by Android-run card payment devices. While the latter provide a better payment experience for businesses and customers, at the same time they have a higher cost and are too vulnerable to dust, liquids and shocks. At a restaurant, cafe, car rental company or even a petrol station, minor accidents with a POS are likely to occur and the cost of replacing a POS terminal with a printer is not negligible. Christo G

TREKSTOR Donates 100.000 FFP2 Respirators to Tafel Deutschland e.V.28.1.2021 13:43:00 EETPress release

Today the TREKSTOR GmbH, the manufacturer behind the blnk branded healthcare products, completed delivery of 100.000 FFP2 class respirators to the Tafel Deutschland. This is a reaction to the increased demand for certified PPE products created by both decisions of the federal government as well as the FFP2 mandate active in the state of Bavaria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005522/en/ A volunteer at Tafel Bayern takes possession of and inspects the donated FFP2 respirators. (Photo: Business Wire) „As a German company, which mainly exists today due to the sales of entry-level PCs and tablets to price-sensitive customers in the past, we are aware of our responsibility to our fellow citizens“, Shimon Szmigiel, CEO of TREKSTOR, explains. „Many of them are lagging the financial prowess to purchase high quality protective equipment, a state that is worsened by lay-offs and short-time work arrangements.” The

TATA Technologies Actuates New Entity, TATA Technologies NORDICS AB in Sweden28.1.2021 13:33:00 EETPress release

Tata Technologies, a leading global engineering and product development digital services company, has commenced operations in its wholly owned subsidiary in Gothenburg, Sweden. This move marks the completion of its acquisition deal with Escenda AB in 2017. Sweden and the overall Nordics region holds strategic importance for the new entity, considering the presence of global OEMs and Tier 1 automotive majors, large export volumes, and augmented focus on vehicle electrification. Tata Technologies’ mission is to help the clients Engineer the better products and there are two key components to the company’s value proposition; the first one being outsourced product engineering services for our clients helping them conceptualize and design better products, and the second one is helping them manufacture and realize better products. Through the new delivery centre, Tata Technologies will offer its expansive portfolio of solutions covering entire product engineering value chain to customers acr

Seoul Viosys Begins Mass Production of 25Gbps VCSELs for 5G Communication Applications28.1.2021 11:40:00 EETPress release

Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor provider, announced that for the first time in Korea, Seoul Viosys succeeded in developing vertical cavity surface emitting laser (VCSEL) technology, a near-field-only 25Gbps laser diode compatible with 5G wired networks for transmitting and receiving, and has started mass production to supply these products to three initial customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005444/en/ [Figure 1] Schematic diagram of 5G network application using Seoul Viosys’ VCSELs (Graphic: Business Wire) VCSEL is a laser diode technology that converts electrical signals into optical signals. It has recently attracted attention as a light-based communication technology that achieves ultra-high-speed data communication in 5G environments. This technology is necessary for AR/VR, 3D sensing and the camera-applied ToF (Time of Flight) for smartphones, and automotive L

REPLY: Spike Reply and Storm Reply Achieve AWS Security Competency Status28.1.2021 11:30:00 EETPress release

Reply announced today that its companies Storm Reply and Spike Reply achieved Amazon Web Services (AWS) Security Competency status. This designation recognizes that the two companies of the Reply Group have demonstrated deep expertise that helps customers achieve their cloud security goals. Achieving the AWS Security Competency differentiates Storm Reply and Spike Reply as AWS Partner Network (APN) members that provide specialized consultancy services and integrated solutions designed to help enterprises adopt, develop and deploy complex security projects on AWS. To receive the designation, APN Partners must possess deep AWS expertise and deliver solutions seamlessly on AWS. Filippo Rizzante, CTO Reply, commented: “We are proud to be among the first APN partners to achieve AWS Security Competency status. This AWS competency status confirms the ability of our teams in helping companies achieve their security goals by combining our expertise with the range of powerful security tools that

Neustar highlights rise in ransom-related DDoS attacks and greater use of existing attack vectors28.1.2021 11:30:00 EETPress release

Neustar, Inc., a global information services and technology company and leader in identity resolution, has today published its report entitled ‘Cyber Threats and Trends: Pandemic Style’, detailing the security risks faced by companies as the COVID-19 pandemic accelerated the digital revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005015/en/ Figure 1: Percentage change in number of attacks by size category, 2020 vs. 2019 (Graphic: Business Wire) Informed by data from Neustar’s Security Operations Center (SOC), the report reveals a 154 percent increase in the number of attacks between 2019 and 2020, with growth in ransom-related DDoS (RDDoS) attacks and a rise in use of existing attack vectors, including web applications. The report also provides key details around the amount, size, duration and intensity of DDoS attacks throughout 2020 to keep cyber security professionals informed. DDoS ransom attacks on the

STC calls on ADVA’s NFV suite for uCPE services28.1.2021 11:00:00 EETPress release

ADVA (FSE: ADV) today announced that the Saudi Telecom Company (STC) is rolling out on-demand virtual services using ADVA’s Ensemble suite of network functions virtualization (NFV) technologies. The new universal CPE (uCPE) offering is built on the Dell EMC Networking Virtual Edge Platform (VEP) 1405 series running ADVA’s Ensemble Edge Cloud NFV suite. Enterprise customers of STC, the largest IT service provider in the Middle East, will be able to quickly and easily access virtual services, including routing, firewall, WAN optimization, IoT and voice applications. With the industry’s largest ecosystem of virtual network functions (VNFs) to choose from, managed service customers can automatically enable new applications and services without any financial risk. “Today’s enterprises need to be agile. They require the freedom to mix and match the latest cloud technologies to seize new revenue opportunities in an instant. That’s what our new uCPE service is all about. It eliminates vendor l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom